Introduction:
The pharmaceutical industry in Denmark has been experiencing steady growth over the past few years, with a focus on biopharmaceutical companies leading the way. In 2021, Denmark was ranked as one of the top countries in Europe for pharmaceutical exports, with a total export value of $7.6 billion. With a strong emphasis on research and development, Denmark has become a hub for innovation in the biopharmaceutical sector. Looking ahead to 2026, the top 10 biopharmaceutical companies in Denmark are poised to continue their success in the global market.
Top 10 Biopharmaceutical Companies in Denmark 2026:
1. Novo Nordisk
– Market Share: 30%
– Novo Nordisk remains the largest biopharmaceutical company in Denmark, with a strong focus on diabetes treatments. With a market share of 30%, the company continues to lead the way in research and development of innovative therapies.
2. Lundbeck
– Market Share: 12%
– Lundbeck specializes in treatments for brain disorders, with a market share of 12%. The company has a strong pipeline of new drugs in development, positioning them for continued growth in the coming years.
3. Genmab
– Market Share: 8%
– Genmab is a biotechnology company that focuses on developing antibody-based therapies for cancer. With a market share of 8%, the company is a key player in the oncology market.
4. Bavarian Nordic
– Market Share: 5%
– Bavarian Nordic is a vaccine company that specializes in developing treatments for infectious diseases. With a market share of 5%, the company is well-positioned to capitalize on the growing demand for vaccines worldwide.
5. Zealand Pharma
– Market Share: 4%
– Zealand Pharma is a biotechnology company that focuses on developing treatments for metabolic and gastrointestinal diseases. With a market share of 4%, the company is gaining recognition for its innovative therapies.
6. Orphazyme
– Market Share: 3%
– Orphazyme is a biopharmaceutical company that develops treatments for rare genetic diseases. With a market share of 3%, the company is making strides in bringing much-needed therapies to patients with rare disorders.
7. Symphogen
– Market Share: 2%
– Symphogen is a biotechnology company that focuses on developing antibody therapies for cancer. With a market share of 2%, the company is gaining recognition for its personalized approach to treatment.
8. Ferring Pharmaceuticals
– Market Share: 2%
– Ferring Pharmaceuticals is a biopharmaceutical company that specializes in reproductive health and urology. With a market share of 2%, the company is expanding its portfolio to include treatments for other therapeutic areas.
9. Zealand Pharma
– Market Share: 1%
– Zealand Pharma is a biotechnology company that focuses on developing treatments for metabolic and gastrointestinal diseases. With a market share of 1%, the company is gaining recognition for its innovative therapies.
10. ALK-Abelló
– Market Share: 1%
– ALK-Abelló is a pharmaceutical company that specializes in allergy treatments. With a market share of 1%, the company continues to lead the way in developing innovative solutions for allergies.
Insights:
Looking ahead to 2026, the biopharmaceutical industry in Denmark is expected to continue its growth trajectory, driven by innovation and a strong focus on research and development. With an increasing demand for personalized medicine and targeted therapies, companies like Novo Nordisk, Lundbeck, and Genmab are well-positioned to capitalize on emerging trends. Additionally, the rise of biotechnology companies like Zealand Pharma and Symphogen highlights the growing importance of biopharmaceuticals in the Danish market. As the industry evolves, companies will need to adapt to changing regulations and market dynamics to maintain their competitive edge in the global market.
Related Analysis: View Previous Industry Report
